Communiqués UCB

Actions

UCB

BE0003739530

Produits pharmaceutiques

Marché Fermé - Euronext Bruxelles Autres places de cotation 17:55:00 03/07/2026			Varia. 5j.	Varia. 1 janv.
259,50 ^EUR	-1,93%		+0,39%	+8,76%

03/07	Berenberg ajuste l'objectif de cours et les previsions d'UCB apres les recentes acquisitions de pipeline	MT
25/06	États-Unis : le prix des nouveaux médicaments a reculé en 2025, porté par la baisse des lancements de thérapies géniques coûteuses	RE

Communiqués

03/07	UCB : FASTRAX working session highlights progress in axSpA diagnosis	PU
30/06	Changing the Way We Care for gMG: Why Patient Choice and Innovation Must Lead the Way	PU
17/06	UCB : completes acquisition of Candid Therapeutics, strengthening next generation immunology pipeline	PU
12/06	Reflections from EULAR 2026: advancing early control of inflammation	PU
05/06	UCB - EULAR 2026, Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus	AQ
05/06	UCB : New EULAR 2026 data show CIMZIA (certolizumab pegol) delivered consistent effect in rheumatoid arthritis, regardless of rheumatoid factor (RF) levels	PU
03/06	UCB : BIMZELX(bimekizumab) data at EULAR 2026 show early and sustained inflammation control can improve patient reported outcomes and limit disease progression in PsA and axSpA	PU
02/06	UCB : completes acquisition of Neurona Therapeutics, advancing its leadership as innovator in epilepsy through regenerative science	PU
02/06	UCB : presents research at EUROMIT 2026 highlighting burden of care, need for earlier diagnosis, and impact of pyrimidine nucleoside therapy on people living with TK2d	PU
01/06	UCB : and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus	PU
20/05	UCB : Financial Reporting Document	PU
19/05	BIMZELX[®](bimekizumab) demonstrates superior efficacy over SKYRIZI[®] (risankizumab) in psoriatic arthritis: BE BOLD Week 16 data	PU
08/05	UCB : Celebrating a decade of partnership advancing digital innovation in epilepsy care	PU
07/05	UCB : Cancer Research UK and Cancer Research Horizons announce new strategic alliance to accelerate development of novel cancer therapies	PU
04/05	UCB announces acquisition of IMIDomics Patient Insight Business, strengthening capabilities in immune-mediated inflammatory diseases	AQ
03/05	UCB : to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers	PU
01/05	UCB : announces acquisition of IMIDomics’ Patient Insight Business, strengthening capabilities in immune-mediated inflammatory diseases (IMIDs)	PU
30/04	UCB : General Meeting of Shareholders 2026	PU
24/04	UCB : Inside UCB’s new gene therapy facility	PU
17/04	UCB : to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science	PU
15/04	UCB : presents new data demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN 2026 meeting	PU
13/04	UCB - Acquisition of own shares	AQ
10/04	UCB : Acquisition of own shares	PU
31/03	UCB : European Commission approves KYGEVVI▼ (doxecitine and doxribtimine) as first and only treatment for Thymidine Kinase 2 Deficiency (TK2d)	PU
27/03	UCB : Annual General Meeting of Shareholders 2026	PU